ACTIVE

ABBVIE

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result6,4 M €-3,0 %over 1 year

Revenue265,6 M €+13,9 %over 1 year

Equity182,7 M €-1,5 %over 1 year

Workforce213,4 ETP+6,3 %over 1 year

Identity

Source · BCE/KBO

ABBVIE is a Public limited company incorporated in 2012. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Wavre. It employs on average 213,4 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0845.096.860
Incorporation: 05/04/2012
Legal form: Public limited company
Registered office: Avenue Einstein 14
1300 Wavre · WallonieSee on map
Contributed capital: 166 088 088,10 €
Latest accounts: 31/12/2025
Average workforce: 213,4 ETP

Activities (NACE)

46460Wholesale of pharmaceutical goods· main 46460Wholesale of pharmaceutical goods

Joint committees (1)

Signals

ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHigh revenue

Financials

Source · NBB, 14 filings

Trend over 7 financial years

	2025		2024		2023		2018		2017
Income statement
Revenue	265,6 M €	+13.9%	233,2 M €	+20.6%	193,3 M €	-3.6%	200,6 M €	+8.9%	184,2 M €
EBITDA	12,5 M €	+9.7%	11,4 M €	+26.7%	9 M €	+12316%	-73,7 k €	+99.3%	-11,3 M €
Operating result	9 M €	+18.9%	7,6 M €	+16.5%	6,5 M €	+942%	-770,5 k €	+93.8%	-12,5 M €
Net result	6,4 M €	-3.0%	6,6 M €	+5.9%	6,3 M €	+396%	-2,1 M €	-105%	43,2 M €
Balance sheet
Equity	182,7 M €	-1.5%	185,6 M €	-4.8%	194,9 M €	+152%	77,4 M €	-2.7%	79,5 M €
Total assets	227,4 M €	-1.8%	231,4 M €	-3.4%	239,5 M €	+106%	116,1 M €	-5.1%	122,4 M €
Cash	–		–		52,9 k €		–		–
Debts	41,4 M €	-5.4%	43,8 M €	-0.2%	43,9 M €	+19.0%	36,8 M €	-11.4%	41,6 M €
Other
Workforce	213,4 ETP	+6.3%	200,8 ETP	+5.0%	191,3 ETP	+34.2%	142,6 ETP	-3.1%	147,2 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 50 M€ and 100 M€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

5 active · 9 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Erica Silbiger	Director01/04/2026 → 26/05/2028
Rolfe van de Spreng	Director01/12/2025 → 31/03/2026
Renaud Decroix	Chairman of the board of directors01/08/2020 → 28/05/2027
Arnaud Jean Jacques Coint-Bavarot	Director01/05/2022 → 29/05/2026
Jean Antoine De Los Frailes	Director08/12/2017 → 29/05/2026

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Meike Elisabeth Celine Colette Kerstens	Director01/05/2022 → 2023 accounts
Robert Andrew Michael	Directorlisted until the 2018 accounts
, Ernst & Young Réviseurs d'Entreprises SCCRL (B160)	Auditor27/05/2016 → 2018 accounts
Thibault Massart	Chairman of the board of directors11/05/2016 → 2018 accounts

Other companies at this address

Avenue Einstein 14 1300 Wavre

Company	CBE no.
ABBOTT● Active	0403.044.007
SYNDESI THERAPEUTICS● Active	0686.599.355

Full financial information

Source · NBB

	2025	2024	2023	2022	2021	2020
Type of account	Full model	Full model	Full model	Full model	Full model	Full model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	08/06/2026	17/06/2025	07/06/2024	12/06/2023	09/06/2022	09/06/2021
General meeting	29/05/2026	30/05/2025	31/05/2024	26/05/2023	30/05/2022	28/05/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 14 filings

Model	Closing	General meeting	Filed	Language	Document
Full model	31/12/2025	29/05/2026	08/06/2026	French	PDF
Full model	31/12/2024	30/05/2025	17/06/2025	French	PDF
Full model	31/12/2023	31/05/2024	07/06/2024	French	PDF
Full model	31/12/2022	26/05/2023	12/06/2023	French	PDF
Full model	31/12/2021	30/05/2022	09/06/2022	French	PDF
Full model	31/12/2020	28/05/2021	09/06/2021	French	PDF
Full model	31/12/2019	29/05/2020	30/06/2020	French	PDF
Full model	31/12/2018	31/05/2019	22/07/2019	French	PDF
Full model	31/12/2017	25/05/2018	20/06/2018	French	PDF
Full model	31/12/2016	26/05/2017	22/06/2017	French	PDF
Full model	31/12/2015	27/05/2016	01/07/2016	French	PDF
Full model	31/12/2014	29/05/2015	24/06/2015	French	PDF
Full model	31/12/2013	30/05/2014	19/06/2014	French	PDF
Full model	31/12/2012	31/05/2013	01/08/2013	French	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 50 M€ and 100 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

5 active · 9 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Erica Silbiger	Director01/04/2026 → 26/05/2028
Rolfe van de Spreng	Director01/12/2025 → 31/03/2026
Renaud Decroix	Chairman of the board of directors01/08/2020 → 28/05/2027
Arnaud Jean Jacques Coint-Bavarot	Director01/05/2022 → 29/05/2026
Jean Antoine De Los Frailes	Director08/12/2017 → 29/05/2026

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Meike Elisabeth Celine Colette Kerstens	Director01/05/2022 → 2023 accounts
Robert Andrew Michael	Directorlisted until the 2018 accounts
, Ernst & Young Réviseurs d'Entreprises SCCRL (B160)	Auditor27/05/2016 → 2018 accounts
Thibault Massart	Chairman of the board of directors11/05/2016 → 2018 accounts

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette

Mandates10/07/2026
Renouvellement du mandat d'un administrateur
PDF
Mandates07/05/2026
DEMISSIONS, NOMINATIONS
PDF
Mandates06/01/2026
DEMISSIONS, NOMINATIONS
PDF
Mandates03/09/2025
DEMISSIONS, NOMINATIONS
PDF
Mandates19/06/2024
DEMISSIONS, NOMINATIONS
PDF
Mandates17/04/2024
DEMISSIONS, NOMINATIONS
PDF
Mandates22/12/2023
DEMISSIONS, NOMINATIONS
PDF
Mandates11/07/2023
DEMISSIONS, NOMINATIONS
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts

Year

Identity

Incorporation

Name

Registered office

Annual accounts

Filings7 filings

Mandates

Erica Silbiger

Rolfe van de Spreng

Renaud Decroix

Arnaud Jean Jacques Coint-Bavarot

Jean Antoine De Los Frailes

Meike Elisabeth Celine Colette Kerstens

Robert Andrew Michael

, Ernst & Young Réviseurs d'Entreprises SCCRL (B160)

Thibault Massart

Jean-Louis Gantmacher

Jaroslaw OLESZCZUK

Valérie BUYSE

Show the 2 other mandates

20122013201420152016201720182019202020212022202320242025202620272028

ABBVIE

Avenue Einstein 14, 1300 Wavre

Director

Chairman of the board of directors

Director

Auditor

Chairman of the board of directors

Director

CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE

Registered address	Period	Source
Avenue Einstein 14, 1300 WavreCurrent	accounts 2023 → 2025	Accounts 2025 · 2026-00155854

Company names

Source · NBB annual accounts, CBE

Name	Period	Source
ABBVIECurrent	accounts 2023 → 2025	Accounts 2025 · 2026-00155854

Events

01/04/2026
nominationErica Silbiger · administrateur
2025
Annual accounts 20256,4 M €↓
01/12/2025
nominationRolfe van de Spreng · administrateur
30/05/2025
reconductionEY Reviseurs d'Entreprises SRL · Commissaire
2024
Annual accounts 20246,6 M €↑
31/05/2024
reconductionRenaud Decroix · administrateur délégué et Président du Conseil d'administration
2023
Annual accounts 20236,3 M €↑
17/10/2023
nominationThomas Meurice · représentant permanent du cabinet de révision (commissaire)
13/06/2023
nominationScott Reents · Chief Financial Officer (membre du comité bancaire)
13/06/2023
nominationLindsey Bristow · Vice President of Tax (membre du comité bancaire)
13/06/2023
nominationPatrick Johannes Albers · Manager Treasury Operations (membre du comité bancaire)
13/06/2023
nominationJohannes Christiaan Dunnik · Manager Treasury Operations (membre du comité bancaire)
13/06/2023
nominationRadoika Djurdjic · Managing Director de AbbVie Central Finance BVs (membre du comité bancaire)
13/06/2023
nominationWayne Klintworth · Assistant Treasurer (membre du comité bancaire)
26/05/2023
reconductionJean Antoine De Los Frailes · administrateur
30/05/2022
reconductionEY Réviseurs d'Entreprises · commissaire
2018
Annual accounts 2018-2,1 M €↓
2017
Annual accounts 201743,2 M €↓
2016
Annual accounts 201656,4 M €↑
2015
Annual accounts 2015-4,5 M €
05/04/2012
IncorporationPublic limited company

ABBVIE

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline

Registered offices

Company names

Events